KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBT (2016 - 2025)

Historic EBT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$162.5 million.

  • CRISPR Therapeutics AG's EBT fell 10878.69% to -$162.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$610.5 million, marking a year-over-year decrease of 5115.04%. This contributed to the annual value of -$610.5 million for FY2025, which is 5115.04% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's EBT stood at -$162.5 million, which was down 10878.69% from -$105.8 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's EBT registered a high of $763.4 million during Q2 2021, and its lowest value of -$207.3 million during Q2 2025.
  • In the last 5 years, CRISPR Therapeutics AG's EBT had a median value of -$118.6 million in 2022 and averaged -$73.4 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's EBT soared by 106291.23% in 2021, and later crashed by 23144.05% in 2024.
  • CRISPR Therapeutics AG's EBT (Quarter) stood at -$143.5 million in 2021, then rose by 15.42% to -$121.4 million in 2022, then surged by 148.79% to $59.2 million in 2023, then tumbled by 231.44% to -$77.8 million in 2024, then plummeted by 108.79% to -$162.5 million in 2025.
  • Its last three reported values are -$162.5 million in Q4 2025, -$105.8 million for Q3 2025, and -$207.3 million during Q2 2025.